Tivozanib (hydrate) – 10 mg

Brand:
Cayman
CAS:
682745-40-0
Storage:
-20
UN-No:
Non-Hazardous - /

Tivozanib is an orally available, selective VEGFR inhibitor with IC50 values of 0.21, 0.16, and 0.24 nM for VEGFR1, VEGFR2, and VEGFR3, respectively.{19939,32739} It can also inhibit c-Kit and PDGFRβ with IC50 values of 1.63 and 1.72 nM, respectively.{32739} When administered to athymic rats, tivozanib was shown to decrease the microvessel density within tumor xenografts and attenuate VEGFR2 phosphorylation levels in tumor endothelium.{32739} It also displays antitumor activity against a wide variety of human tumor xenografts, including lung, breast, colon, ovarian, pancreas, and prostate cancer.{32739}  

 

Available on backorder

SKU: - Category:

Description

An orally available, selective VEGFR inhibitor (IC50s = 0.21, 0.16, and 0.24 nM for VEGFR1, VEGFR2, and VEGFR3, respectively); also inhibits c-Kit and PDGFRβ (IC50s = 1.63 and 1.72 nM, respectively)


Formal name: N-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N’-(5-methyl-3-isoxazolyl)-urea, monohydrate

Synonyms:  AV-951|KRN 951

Molecular weight: 472.9

CAS: 682745-40-0

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|PDGFR Family||Product Type|Biochemicals|Kinase Inhibitors|VEGFR Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Angiogenesis||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling